• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

ArcaScience Raises $7M to Advance AI-Powered Drug Benefit-Risk Evaluation

by Fred Pennic 09/03/2025 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
ArcaScience Raises $7M to Advance AI-Powered Drug Benefit-Risk Evaluation

What You Should Know: 

– ArcaScience, a Paris, France-based AI Healthtech startup, has announced a $7M seed funding round led by The Moon Venture, with participation from Pléiade Venture, Plug&Play Ventures, Bpifrance, and AKKA Technologies. This marks the company’s first institutional funding round, following a €1.3 million pre-seed raise.

– The new funds will be used to expand operations in the U.S. and U.K., launch the company’s first patient-facing solution, and strategically recruit a Chief Medical Officer. The initial focus for the patient-facing solution will be on pediatric brain cancer and dermatological diseases.

Evaluating The Benefit-Risk Profile of New Drugs

ArcaScience was born out of founder Romain Clement’s personal experience with brain cancer. After his remission, he set out to address the blind spots in how pharmaceutical companies evaluate the benefit-risk profile of new drugs. Founded to address this critical bottleneck in drug development, ArcaScience has pioneered the use of AI to improve benefit-risk assessments for pharmaceuticals and regulators, empowering both clinical teams and patients.

The company’s CEO, Romain Clement, stated that it takes more than 10 years to bring a drug to market, with a 90% failure rate and an average cost of $2.3 billion for a drug that succeeds. He noted that this funding will help ArcaScience scale its product and bring “real benefit-risk clarity to both the pharma industry and patients”.

Global Traction and Strategic Partnerships

Experts predict that by 2026, 80% of pharmaceutical companies will rely on AI solutions for benefit-risk evaluation. ArcaScience is already seeing traction from this shift, with 10 pharma clients, including Sanofi, AstraZeneca, GSK, Takeda, and ICON. The company is also a member of a new pan-European consortium created by Sanofi and Imagine for Margo that is focused on combating pediatric brain cancer with AI.

ArcaScience’s platform has been used by over 70,000 patients in the area of chronic skin diseases and is being adopted by clinical operations and pharmacovigilance leaders to derisk clinical trials and optimize drug development. The company was also selected by the French government during the COVID-19 crisis to structure and deliver the complete corpus of scientific knowledge on the virus, which is a testament to the platform’s robustness and reliability. The company’s proprietary platform combines 24 highly specialized AI models with a single database of 100 billion health data.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Artificial Intelligence, Drug Discovery

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Interview

The AI Paradox in Healthcare: Notable CEO Shares Why Moving Too Slowly is a Greater Risk

Most-Read

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

RevSpring to Acquire Kyruus Health, Creating a Unified Patient Experience

RevSpring to Acquire Kyruus Health, Creating a Unified Patient Experience

Oracle Confirms Layoffs in Kansas City

Oracle Confirms Layoffs in Kansas City

Philips Future Health Index 2025: AI and Digital Tech Can Help Solve Cardiac Care Crisis

Philips Future Health Index 2025: AI and Digital Tech Can Help Solve Cardiac Care Crisis

Optain Health Secures $26M to Advance AI-Powered Retinal Screening

Optain Health Secures $26M for AI-Powered Retinal Screening

Sutter Health and Epic Launch "Sutter Sync" to Optimize Remote Chronic Care

Sutter Health and Epic Launch “Sutter Sync” to Optimize Remote Chronic Care

Patient Square Capital Acquires Premier in $2.6B Deal

Pfizer Acquires Metsera for $4.9B, Expanding into Obesity and Cardiometabolic Market

Pfizer Acquires Metsera for $4.9B, Expanding into Obesity and Cardiometabolic Market

CVS Health Subsidiary Omnicare Files for Bankruptcy to Tackle Financial Challenges

CVS Health Subsidiary Omnicare Files for Bankruptcy to Tackle Financial Challenges

Corti Joins Coalition for Health AI to Advance Responsible and Safe AI in Healthcare

Joint Commission and CHAI Release First-Ever Guidance for Responsible AI in Healthcare

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |